← All diseases
Cancer
Liver cancer
Do you want to receive a message when there is new research about Liver cancer? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence above each publication explains what was studied — and you'll be notified as soon as new research on Liver cancer is available. View what Premium costs.
Publications and studies (3362)
- METTL3 promotes proliferation and invasion and inhibits ferroptosis in hepatocellular carcinoma by mediating m6A methylation modification of NUPR1. (2026/08/07) ♡
- Spatiotemporal dynamics of the tumor microenvironment in hepatocellular carcinoma during combination immunotherapy. (2026/08/07) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Plant-derived natural products against hepatocellular carcinoma: chemical diversity, mechanisms of action, and organ-based classification. (2026/08/07) ♡
- miR149-5p: A hepatocyte EXOmotif sequence containing microRNA that attenuates liver fibrosis by specifically targeting PDGFRB in HSCs. (2026/08/07) ♡
- Identification of CLIC1 as a direct molecular target of luteolin associated with ferroptosis induction in hepatocellular carcinoma. (2026/08/07) ♡
- Liver cells-derived extracellular vesicles deliver a dual-functional RNA ligand for TACE treatment of hepatocellular carcinoma. (2026/08/07) ♡
- Quercetin, an ingredient of Jiedu Xiaozheng Yin, alleviates hepatocellular carcinoma progression by regulating CYP1A2/PTEN/PI3K/Akt axis. (2026/08/07) ♡
- Dual-Switchable Nanoparticles Resolving the Safety-Efficacy Paradox of Sonodynamic Immunotherapy for Hepatocellular Carcinoma. (2026/08/07) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The interplay between chronic inflammation and tumorigenesis: unraveling the inflammation-driven axis. (2026/08/07) ♡
- BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma. (2026/08/07) ♡
- Successful Long-Term Survival With Various Modalities of Treatments Combining Minimally Invasive Surgery for Intrahepatic and Extrahepatic Recurrence of Hepatocellular Carcinoma: A Case Report. (2026/08/07) ♡
- Robotic Whole-graft Liver Transplant: Lesson Learned And Outcomes After 45 Cases. (2026/08/06) ♡
- Comparative Evaluation of Adaptive Focused Acoustics- and SP3-Based Workflows for Deep Proteomic Profiling of 30-Year-Old Formalin-Fixed Paraffin-Embedded Tissues. (2026/08/06) ♡
- Non-canonical mTORC1-TFEB activation promotes hepatocyte plasticity and high-grade malignancy in hepatocellular carcinoma. (2026/08/06) ♡
- Sodium Glucose Co-Transporter 2 Inhibitors Use in Diabetic Patients with Cirrhosis Improves Liver-related Outcomes and Survival. (2026/08/06) ♡
- C1R suppresses hepatocellular carcinoma cell aggressiveness through promoting HIF-1α degradation and modulating cuproptosis-related protein expression. (2026/08/06) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Calotropis gigantea (L.) Dryand. Stem bark extract suppresses tumor angiogenesis through modulation of HIF-1α/VEGF signaling and ERK1/2-AKT activation in HepG2 xenograft-bearing nude mice. (2026/08/06) ♡
- Integrative multi-omics and experimental validation reveal the oncogenic role of DDX52 in liver hepatocellular carcinoma. (2026/08/06) ♡
- Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC. (2026/08/06) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC). (2026/08/06) ♡
- Disruption of RBPJ in liver cancer-infiltrating T cells enhances antitumor immunity through remodeling epigenetic landscape. (2026/08/06) ♡
- HIF-1α-associated transcriptional responses to chemical hypoxia in breast and liver cancer cells. (2026/08/06) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Response to the Letter Regarding "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial". (2026/08/06) ♡
- Transcatheter arterial embolization for massive hepatocellular carcinoma in 18 dogs (2020-2025). (2026/08/06) ♡
- A Chemotherapy Progression Decision Score for Treatment Selection After Initial Assessment in Pancreatic Ductal Adenocarcinoma. (2026/08/06) ♡
- A cigarette compound-induced tumor microenvironment promotes sorafenib resistance in hepatocellular carcinoma via the 14-3-3η-modified tumor-associated proteome. (2026/08/05) ♡
- Nicotinamide riboside enhances adoptive T cell therapy by promoting memory differentiation and metabolic fitness. (2026/08/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Acromegaly and Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical and Therapeutic Implications. (2026/08/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clinical Relevance of Bile Acid and Bile Acid-Related Therapy in Liver Cirrhosis: A Review. (2026/08/05) ♡
- FKBP52 dictates the dual role of p53 in hepatocellular carcinoma: mutation-specific prognostic stratification and therapeutic implications. (2026/08/05) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Can one dissemination time be assigned to polyclonal hepatocellular carcinoma recurrence? (2026/08/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Applications of FDG-PET Imaging in the Management of Patients with Hepatobiliary and Pancreatic Tumors. (2026/08/05) ♡
- Patient awareness of viral hepatitis infection in Al-Madinah, Saudi Arabia: a cross-sectional study. (2026/08/05) ♡
- Baseline ALBI Grade as an Independent Prognostic Factor of Survival in High-Risk Real-World HCC Under Atezolizumab-Bevacizumab. (2026/08/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Metabolic Modulation for Liver Regeneration in Hepatocellular Carcinoma: From Biological Mechanisms to Precision Regenerative Medicine. (2026/08/05) ♡
- Nanoscale copper ethoxide enables immunologically enhanced hepatoma radio-immunotherapy via synergistic cuproptosis and metabolic oxidative stress. (2026/08/05) ♡
- Characterization of hepatocellular carcinoma patient-derived organoids from patients receiving transarterial chemoembolization as a model for preclinical drug response assessment. (2026/08/04) ♡
- An oxidative stress - and immunotherapy-related six-gene signature defines immune subtypes and predicts prognosis and immunotherapy response in hepatocellular carcinoma. (2026/08/04) ♡
- β-glucan elicits APOE-dependent peripheral trained immunity to suppress hepatocellular carcinoma. (2026/08/04) ♡
- A Single‑Center Retrospective Cohort Study: Impact of Glycemic Control on First‑Line TKI Plus PD‑1 Inhibitors versus TKI Alone in Intermediate‑to‑advanced Unresectable Hepatocellular Carcinoma(HCC) with Type 2 Diabetes Mellitus (T2DM). (2026/08/04) ♡
- EMBC Special Issue: SAM-HovNet: SAM-Enhanced Multi-Class Nucleus Segmentation and Classification in Hepatocellular Carcinoma Slides. (2026/08/04) ♡
- Aggressive Histologic Subtypes Drive Poor Outcomes after Percutaneous Ablation for Early Recurrent Hepatocellular Carcinoma. (2026/08/04) ♡
- Detailed racial/ethnic disparities in hepatocellular carcinoma risk with an electronic health record-based cohort. (2026/08/04) ♡
- Metabolic Dysfunction-Associated Steatotic Liver Disease Reprograms the Hepatic Metastatic Niche. (2026/08/04) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Diffusion-Weighted Imaging-Based Virtual MR Elastography of the Liver: Beyond Mechanical Waves. (2026/08/04) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Beyond Diagnosis: Magnetic Resonance Imaging-Based Imaging Biomarkers for Tumor Biology, Prognosis, and Clinical Decision-Making in Hepatocellular Carcinoma. (2026/08/04) ♡
- Hepatocyte MLKL drives obesity-driven hepatocellular carcinoma progression via mitochondrial dysfunction independent of necroptosis in MASLD. (2026/08/04) ♡
- Computational screening of natural compounds reveals glycyrrhisoflavone as a potential Hepatitis B X-interacting protein inhibitor. (2026/08/03) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A 19-Year-Old Woman With Pulmonary and Vertebral Lesions Suggestive of Metastatic Hepatocellular Carcinoma. (2026/08/01) ♡
- TALDO1 promotes lipid metabolic reprogramming and immunosuppressive microenvironment remodelling in hepatocellular carcinoma. (2026/08/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.